Community Research and Development Information Service - CORDIS

Results 1 - 10 of 94
12 3 4 5 6 7 8 9 10 > 
Accelerating HIV Cure in Europe
[PROJECT] EU4HIVCURE - Accelerating HIV Cure in Europe
ID: 691119
Start date: 2016-02-01, End date: 2020-01-31
Finding a CURE for 35 Million individuals living with HIV/AIDS is one of the great global health challenges of the 21st century. The major obstacle to HIV eradication is the persistence of latent HIV cellular reservoirs, where the integrated viral genome is transcriptionally...
Programme: H2020-EU.1.3.3.
Record Number: 199940
Last updated on: 2016-06-30
European AIDS Vaccine Initiative 2020
ID: 681137
Start date: 2015-11-01, End date: 2020-10-31
HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the...
Programme: H2020-EU.3.1.
Record Number: 198798
Last updated on: 2017-08-17
Glucose metabolism and mTOR pathway role in CD8+ T cell control of HIV-1
ID: 706871
Start date: 2016-04-01, End date: 2018-03-31
Antiretroviral therapy can decrease HIV-1 below the limit of detection but fails to eliminate the virus completely. One of the main goals of a HIV-1 vaccine is the generation of cytotoxic CD8 T cell responses that counteract the virus. CD8 T cells participate in the control of...
Programme: H2020-EU.1.3.2.
Record Number: 201464
Last updated on: 2017-08-05
HIV-1 acquisition and the future of prevention strategies: deciphering the eclipse phase through modelling and phylogenetics
ID: 757688
Start date: 2018-03-01, End date: 2023-02-28
The HIV eclipse phase typically refers to the time between a virus entering a sexually exposed person and detection of viral RNA in their plasma. Of the four phases of HIV-1 infection (eclipse, acute, chronic and AIDS), the eclipse phase is currently the only window of...
Programme: H2020-EU.1.1.
Record Number: 213391
Last updated on: 2018-02-16
Structural and functional characterization of large viral and human non-coding RNA motifs involved in HIV infection
ID: 748759
Start date: 2018-09-01, End date: 2020-08-31
HIV infections cause 1.2Mi deaths/year worldwide at steadily-increasing rates, partly because of antiretroviral resistance and the impossibility of eradicating latent viruses. To expand our understanding of HIV pathogenesis, we need to unravel all molecular mechanisms involved...
Programme: H2020-EU.1.3.2.
Record Number: 210076
Last updated on: 2017-04-21
Analysing the migration choices of HIV-positive gay men in England and France
ID: 747110
Start date: 2018-03-01, End date: 2020-02-29
Despite improvements in available therapies and investments in prevention campaigns, HIV-rates continue to rise across European cities. Gay men are over-represented amongst people with HIV, thus experiencing the combined effects of homophobia and HIV-related stigma. Several...
Programme: H2020-EU.1.3.2.
Record Number: 209239
Last updated on: 2017-03-20
HIV-1 sensing and signaling in dendritic cells
ID: 670424
Start date: 2015-10-01, End date: 2020-09-30
HIV-1 is a major global health problem with over 2 million new infections every year, and although antiretroviral therapy is effective, chronic infected patients suffer from severe co-morbidities due to immune dysfunction. With the proposed SENTINEL project, I aim to identify...
Programme: H2020-EU.1.1.
Record Number: 198710
Last updated on: 2017-01-09
Development of the Cyclin-Dependent Kinase Inhibitor VS2-370 to Target HIV-associated Malignancies and to Purge Viral Reservoir
ID: 762583
Start date: 2017-03-01, End date: 2017-07-31
ViroStatics, operating in the biotechnology industry, is developing the innovative drug VS2-370 that targets both HIV-associated cancer and its indirect cause, the viral infection. There is no similar drug, as HIV infection and associated malignancies are presently treated...
Programme: H2020-EU.2.1.4.
Record Number: 208161
Last updated on: 2017-07-26
Antibody-Mediated Therapy of HIV-1 Infection
ID: 639961
Start date: 2016-01-01, End date: 2020-12-31
Antibodies are destined to neutralize pathogens and can prevent and fight infectious diseases. Over the last years, advances in single B cell cloning resulted in the isolation of highly potent and broad HIV-1 neutralizing antibodies (bNAbs) that have been shown to prevent SHIV...
Programme: H2020-EU.1.1.
Record Number: 199631
Last updated on: 2016-01-20
Understanding HIV-specific B cell function and viral immunogenicity
ID: 757601
Start date: 2018-06-01, End date: 2023-05-31
I will establish how abnormal B cell behaviour contributes to the generation of HIV neutralising antibodies by studying B cell biology: Previous studies show that broadly neutralising HIV antibodies are the most highly-mutated human antibodies ever isolated, with unusually...
Programme: H2020-EU.1.1.
Record Number: 213894
Last updated on: 2018-03-06
12 3 4 5 6 7 8 9 10 > 
List retrieved on: 2018-03-23
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top